Intralesional Rituximab for the Treatment of Conjunctival Indolent Lymphoma

Update Il y a 4 ans
Reference: NCT01514344

Woman and Man

  • | Country :
  • Italy
  • | organs :
  • -
  • | Specialty :
  • -

Extract

Phase II, monocentric, open label study to assess safety and activity of intralesional Rituximab for the treatment of indolent CD20+ lymphoma of conjunctiva.


Inclusion criteria

  • Ocular Adnexal Mucosa-Associated Lymphoid Tissue Lymphoma

Links